Blueprint Medicines Corp. (NASDAQ:BPMC) traded up 4.8% during mid-day trading on Friday . The stock traded as high as $23.20 and last traded at $23.01, with a volume of 90,468 shares trading hands. The stock had previously closed at $21.95.

Several equities research analysts recently issued reports on the company. TheStreet upgraded Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a report on Friday, July 29th. Canaccord Genuity began coverage on Blueprint Medicines Corp. in a report on Friday. They set a “buy” rating and a $26.00 price target on the stock. Raymond James Financial Inc. began coverage on Blueprint Medicines Corp. in a report on Friday, May 27th. They set an “outperform” rating and a $23.00 price target on the stock. Cowen and Company restated a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, May 10th. Finally, Zacks Investment Research downgraded Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Blueprint Medicines Corp. currently has a consensus rating of “Buy” and an average price target of $28.14.

The stock has a 50-day moving average of $20.46 and a 200-day moving average of $18.20. The firm’s market capitalization is $624.51 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.13. The business had revenue of $6.90 million for the quarter, compared to analyst estimates of $3.24 million. The business’s revenue for the quarter was up 961.5% compared to the same quarter last year. Equities analysts predict that Blueprint Medicines Corp. will post ($3.10) earnings per share for the current year.

In other news, CEO Jeffrey W. Albers sold 17,000 shares of the firm’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $20.03, for a total transaction of $340,510.00. Following the sale, the chief executive officer now owns 92,486 shares in the company, valued at $1,852,494.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

A hedge fund recently raised its stake in Blueprint Medicines Corp. stock. RS Investment Management Co. LLC boosted its position in shares of Blueprint Medicines Corp. (NASDAQ:BPMC) by 17.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 740,310 shares of the company’s stock after buying an additional 109,878 shares during the period. RS Investment Management Co. LLC owned 2.73% of Blueprint Medicines Corp. worth $19,500,000 as of its most recent SEC filing.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.